Conroy Kevin T 4
4 · ABBOTT LABORATORIES · Filed Apr 28, 2026
Research Summary
AI-generated summary of this filing
Abbott (ABT) Director Kevin T. Conroy Receives Restricted Stock Award
What Happened
Kevin T. Conroy, a director of Abbott Laboratories (ABT), received a grant of 2,286 restricted stock units (RSUs) on April 24, 2026. The award is reported as 2,286 shares at $0.00 (no cash paid at grant). This is an equity compensation award (not a purchase or sale).
Key Details
- Transaction date: 2026-04-24; Form 4 filed: 2026-04-28 (timely).
- Transaction type/code: Award/Grant (A).
- Shares granted: 2,286 RSUs @ $0.00 (reported acquisition value $0).
- Shares owned after transaction: Not specified in the filing.
- Footnote: Award made under the Abbott Laboratories 2026 Incentive Stock Program; each unit will be paid one-for-one in Abbott common shares upon the earlier of the director’s separation from service, death, or a change in control.
Context
RSUs are a form of deferred equity compensation and do not require an immediate cash purchase or represent an immediate sale. Director RSU grants are common as part of routine board compensation and do not, by themselves, indicate a buy or sell signal. The award will convert to common shares only upon the specified vesting/payment events described above.
Insider Transaction Report
- Award
Common shares without par value
[F1]2026-04-24+2,286→ 133,737 total
Footnotes (1)
- [F1]Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined by the Program).